CTLA4 and hepatocellular carcinoma: For example, combination therapy with RFA plus immune checkpoint inhibitors such as anti-PD-1 [23] and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) [24] was superior to RFA alone in prolonging the survival of HCC patients.